Browsing Tag
Gilead Sciences
56 posts
Is Arcus Biosciences (RCUS) the dark horse of cancer immunotherapy after 26.7-month survival data?
Arcus stock jumped after its domvanalimab-zimberelimab combo showed 26.7-month survival in gastric cancer. Find out what this means for its TIGIT pipeline.
AusperBio raises $63mn series B2 round to advance AHB-137 and expand global hepatitis B
AusperBio raises $63M Series B2 funding to advance AHB-137 pivotal trials, expand its Med-Oligo platform, and reshape the hepatitis B cure race.
Cell therapy in solid tumors: Breakthroughs, delivery challenges, and what’s next
Discover how new trials and biotech innovations are tackling the biggest hurdles in adapting cell therapy for solid tumors. See what’s changing now.
Cognizant’s 2024 revenue hits $19.7bn amid AI-driven growth
Cognizant Technology Solutions Corporation delivered a robust performance in the fourth quarter of 2024, underscoring the effectiveness of…
Cognizant expands AI-driven partnership with Gilead to advance digital transformation in biopharma
Cognizant has reinforced its strategic collaboration with Gilead Sciences in a renewed effort to drive AI-driven solutions and…
Gilead Sciences’ seladelpar gains support as PBC treatment in Europe
In a significant milestone for liver disease therapeutics, Gilead Sciences, Inc. has announced that the Committee for Medicinal…
Dr. Reddy’s joins forces with Gilead Sciences to launch HIV drug Lenacapavir in India and 120 countries
In a historic development for HIV treatment worldwide, Dr. Reddy’s Laboratories has announced a new partnership with Gilead…
Unbelievable cure: German man beats HIV after revolutionary treatment
In a groundbreaking development in the fight against HIV, a 60-year-old German man has been declared free of…
Gilead and Arcus announce significant advancement in metastatic colorectal cancer treatment with etrumadenant plus zimberelimab regimen
Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) have released promising new data from their…
Gilead Sciences completes $4.3bn acquisition of CymaBay Therapeutics to enhance liver disease portfolio
Gilead Sciences, Inc. (Nasdaq: GILD) has officially announced the successful acquisition of CymaBay Therapeutics, Inc. (Nasdaq: CBAY) for…